Lytix Biopharma ASA - PDMR Appendix
Lytix Biopharma ASA: Mandatory notification of trade by primary insider
2026-09-02 22:01:37
Oslo, 2 September 2026 - Eric Falcand, Chair of the Board of Directors and
primary insider in Lytix Biopharma ASA, has today purchased 12,000 shares in
Lytix Biopharma ASA at an average price of NOK 8.3019 per share.
Following the transaction, Eric Falcand holds 12,000 shares in Lytix Biopharma
ASA.
Please refer to the attached notification form for further details.
For further information, please contact:
Gjest Breistein
Chief Financial Officer
E-mail: Gjest.Breistein@lytixbiopharma.com
This information is subject to disclosure under section 5-12 of the Norwegian
Securities Trading Act and Article 19 of the Market Abuse Regulation.
arket Abuse Regulation.\